Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy.

Background/Aim First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab.